Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an ...